Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

U.S. FDA declines to approve United-MannKind's lung disease therapy

Stock MarketsOct 18, 2021 09:23AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly

By Manas Mishra and Bhanvi Satija

(Reuters) -The U.S. Food and Drug Administration declined to approve United Therapeutics (NASDAQ:UTHR) and MannKind (NASDAQ:MNKD) Corp's lung disease therapy, citing an inspection issue at a third-party facility, the companies said on Monday.

The therapy is a drug-device combination that uses United Therapeutics' approved treatment, Tyvaso, in combination with MannKind's portable inhaler.

MannKind's Dreamboat device is a small and portable dry powder inhaler, making its administration more convenient than the traditional nebulized therapy.

MannKind's shares fell 29.3% to $3.60 in premarket trading, while United Therapeutics' shares were down 2.5% at $182.42.

The companies said the agency did not cite any operational shortcomings at MannKind's device manufacturing and testing facility. The inspection was related to a facility that performs analytical testing of a drug substance used in the therapy.

MannKind told Reuters that it remains confident the inspection issue would be resolved "in short order".

The companies were seeking approval of Tyvaso DPI to treat patients with pulmonary arterial hypertension (PAH), as well as PAH associated with interstitial lung disease.

A favorable label for the therapy appears likely, and its approval is a matter of "when" and not "if", J.P. Morgan analyst Jessica Fye said in a note.

While PAH is a type of high blood pressure that affects blood vessels in the lungs, PH-ILDs are a group of diseases that cause inflammation and scarring of the lung tissue, making it harder to breathe.

MannKind and United Therapeutics began collaborating on the pulmonary hypertension product in September 2018. MannKind manufactures the clinical and commercial supplies, while United is responsible for development and regulatory activities.

United said it now expects to launch the product no later than the summer of 2022.

U.S. FDA declines to approve United-MannKind's lung disease therapy
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email